Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: kathleen who wrote (227)	10/27/1999 9:09:00 AM
From: WHL	Respond to of 668

News released just in time for today's TechVest Forum. What an amazing coincidincy! :) October 26, 1999 16:28 Creative BioMolecules Announces New Data Supporting Development of an OP-1-based Therapy for Parkinson's Disease HOPKINTON, Mass.--(BW HealthWire)--Oct. 26, 1999--Creative BioMolecules, Inc. (Nasdaq: CBMI) announced today new data in support of the Company's development of a therapy to treat Parkinson's disease. The data, presented at the Annual Meeting of the Society for Neuroscience, indicates that OP-1 restores dopaminergic neurons in an animal model of Parkinson's disease. Dopamine is a key chemical in the brain which enables coordinated motor movement. Restoring the function of dopaminergic neurons may provide a new therapeutic avenue in the treatment of Parkinson's disease. Creative BioMolecules has an active program in the development of morphogenic protein-based therapies for injury and disease of the central nervous system. Its lead neurological product opportunity in stroke recovery is expected to moved toward clinical investigation with an Investigational New Drug application planned in the third quarter of 2000. The Parkinson's disease research described in this presentation confirms the affect of OP-1 in the central nervous system and provides a longer term product opportunity. "Factors that promote the survival or prevent the progressive deterioration of dopaminergic neurons may have significant benefit in treating Parkinson's disease. This preclinical study indicates that OP-1 can restore dopamine levels in an animal model of the disease," commented Paula C. Bickford, PhD, Associate Professor of Pharmacology at the University of Colorado Health Science Center. In the study, animals were administered OP-1 or a vehicle one week after injury in a rat model of Parkinson's disease. Upon evaluation at week five, animals treated with OP-1 showed a significant increase in dopamine levels in comparison to the vehicle-treated group. A corresponding increase in the enzyme tyrosine hydroxylase, needed for dopamine synthesis, was observed in the substantia nigra of treated rats. The study suggests that OP-1 may promote survival of neurons in the substantia nigra--a region of the brain implicated in Parkinson's disease. The study was conducted by researchers at the University of Colorado and Creative BioMolecules and supported by a Phase I Small Business Innovation Research grant from the National Institutes of Health. Annually, in the United States there are approximately 50,000 newly diagnosed cases of Parkinson's disease adding to the estimated 1,000,000 existing victims. Parkinson's disease has a significant impact on the quality of life of those afflicted. Symptoms include stiffness, tremors, slowness of movement, difficulty with balance, and difficulty in walking. Creative BioMolecules is a biopharmaceutical company developing therapies for human tissue repair and regeneration. The company is focused on morphogenic protein-based therapies to enhance stroke recovery and treat renal disease. Both applications are currently undergoing preclinical development, with the submission of INDs to begin clinical trials expected in 2000. The first product resulting from Creative BioMolecules' technology, the OP-1 Implant(TM) for orthopaedic reconstruction, is licensed to Stryker Corporation and is under regulatory review for approval in the U.S. and Europe. This news release includes forward-looking statements that involve risks and uncertainties. Factors which could cause actual results to differ from the Company's expectations include, without limitation, preclinical demonstration of safety and efficacy in the neurology field, the course of its preclinical and clinical development programs, including the achievement of development milestones by the Company and/or its partners, the initiation, progress and successful completion of human clinical testing, the timely receipt of regulatory approval required for clinical testing, manufacturing and marketing of products, the impact of competitive products, and the other risks and uncertainties detailed from time to time in the Company's periodic reports. NOTE: For additional information, please consult Creative BioMolecules' homepage at creativebio.com. CONTACT: Creative BioMolecules, Inc. Karla MacDonald (617) 912-2953

To: kathleen who wrote (227)	10/29/1999 9:26:00 AM
From: WHL	Read Replies (1) \| Respond to of 668

CBMI just completed its third day of closing under $3.00. We can now proceed up or we may just remain here for a month or two wallowing. But at least the requirement to drive out margin players has been met. That hurdle is no longer a barrier to upward movement in the stock. Cheers!